Tag: Atopic dermatitis
Clinique partners with Icahn School of Medicine to launch skin health center
Clinique, a leading skincare brand, and the Icahn School of Medicine at Mount Sinai have announced a groundbreaking philanthropic partnership to establish the Mount Sinai-Clinique ... Read More
Incyte’s Ruxolitinib Cream demonstrates promising efficacy in TRuE-AD3 study
Incyte (Nasdaq:INCY), an esteemed biopharmaceutical giant, has unveiled compelling expanded findings from its Phase 3 TRuE-AD3 study on the ruxolitinib cream (Opzelura) for treating children ... Read More
Ichnos Sciences strikes exclusive global deal with Astria Therapeutics for OX40 antibody portfolio
Ichnos Sciences, a prominent clinical-stage biotechnology firm specializing in pioneering multispecific antibodies for oncology and under the ownership of Glenmark Pharmaceuticals, has announced a momentous ... Read More
ADX‑629 : Aldeyra Therapeutics kicks off atopic dermatitis phase 2 trial
American biotech company Aldeyra Therapeutics said that it has enrolled the first patient in a phase 2 clinical trial of ADX‑629 for the treatment of ... Read More
Lilly to acquire US dermatology drug company Dermira for $1.1bn
Lilly acquisition of Dermira : US pharma giant Eli Lilly and Company (Lilly) has agreed to acquire California-based dermatology drug company Dermira for about $1.1 ... Read More
Janssen to acquire skin disease drug candidate bermekimab from XBiotech
Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational ... Read More
Arena begins ADVISE clinical trial for etrasimod in atopic dermatitis
Arena Pharmaceuticals has dosed the first subject in the phase 2 ADVISE clinical trial, which is evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis ... Read More
Galderma launches phase 3 atopic dermatitis trial for nemolizumab
Galderma, a Nestle-owned Swiss pharma company, said that it has enrolled the first patients in a phase 3 clinical study evaluating nemolizumab for the treatment ... Read More
LEO Pharma bags licensing rights for atopic dermatitis drug JW1601 from JWP
LEO Pharma, a Danish pharma company, has bagged global exclusive rights for atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP) in a deal worth around ... Read More
Novartis to in-license atopic dermatitis drug MOR106 from MorphoSys, Galapagos
Novartis has agreed to acquire the exclusive global development and marketing rights of atopic dermatitis drug MOR106 from MorphoSys and Galapagos in a deal that ... Read More